Since their method of action are different I suppose there would be no obvious reason not to, as long as IMET doesn't by attaching to Telomerase modify it so much that the immune system stimulated by VAC2 can't recognize and attack cells expressing it. I do however doubt that would be the case.
However I doubt that combination would be tried early in trials but possibly after VAC2 and Imetelstat have been individually validated.
Early results have good efficacy and duration at low "dosage" levels.
Can't come up with the right descriptor for what they do.
Any idea of what a treatment cost would be if they get approval and scale up.
Process is customized for the patient so cannot be too cheap.
Sentiment: Strong Buy
ADXS not CART.
Modified Listeria vector.
Low cost, minimal side effects and out patient injection huge advantages over CAR-T therapies.
Expected synergy with Anti-PD-1/PD L-1
Yes. And the platform although initially aimed at Telomerase expressing cells could be used to target many other ailments that would respond to am immune system attack.
Oral at ASCO to me seems like a pretty big deal.
You don't get to give an oral unless you have something new and significant to describe.
Almost always positive news. Failure is of no interest to others and is usually not presented.
So good news showing extension of the earlier positive AML data from VAV1 should create a solid foundation for VAC2 which has same method of action however using embryo derived Dendritic cells is much cheaper to produce, does not have immune rejection issues to avoid patient specific matching, is consistent in its nature since the cells are all clones and can be frozen and kept at hospitals and used as easily as an off the shelf drug.
As an immune stimulant I hope the trial for VAC2 will include arms with Anti-PD1 and Ant PD-L1 since they should be complementary.
I was extremely disappointed when VAC2 appeared to have been tossed away for peanuts, just prior to starting the Phase I trial in England, even with English funding!!
I actually am discounting OPC1 at this time and putting my future hopes for real success on VAC2.
However useful data from the Phase I is probably at least a year away so maybe OPC1 is the only near term catalyst to watch for.
Getting an oral presentation at ASCO for the follow on data for VAC1 is a big deal.
You don't get an oral without important news, almost always positive.
This will set up the VACII Phase 1 trial starting up in England to be a potential game changer.
Even better the funding for the trial is coming from the British.
Can't believe Geron gave all this away for a pittance.
With AST market cap currently at 75% of Geron's it would appear if Geron had kept the OPC1 and Vac1/2 IP and just let it ride we'd be in great shape.
However AST will soon be releasing follow on data for their VAC1 trial in AML as an oral presentation at ASCO. You don't get an oral slot unless the data is positive. If so it sets up VAC2 which is starting trials in Britain to be a huge game changer.
All potential sold for peanuts by Geron.
#$%$ Yahoo site. I included with that quote that this indicates a strong possibility that IL-12 in combination with Keytruda has a strong possibility of getting at least a 50% response rate, much better than Keytruda monotherapy. If that is the best we get it is still a huge deal.
Intratumoral plasmid IL-12 electroporation promoted local and systemic anti-tumor immunity, Algazi said. Of 26 evaluable patients, 50% had distant lesion regression.
I like Anavex Life Sciences Corp. (AVXL) .
Alzheimers treatment in clinical trial. Shows excellent synergy with Aricept (now available in Generic)
Looked good in Phase I trial and data release for Phase II due in September with intention to immediately move into Phase III.
Huge potential market for Alzheimers plus other neurological diseases caused by same disease mechanism.
Since we still haven't even started the large animal safety trials I'm out until we are into Phase I.
This is dragging out longer than my tolerance level.
Of all the irons in the fire J&J has it's nice to see Geron was picked by Williams as the prime example of a smart company move.
Starting about 2:50 in the piece.
However he was describing what sounded more like Car-T process and not the modified Listeria of Advaxis although he did name Advaxis as the company responsible. ??
Actually Geron, I believe Gryaznov had noted GRN163L had a high degree of acid resistance.
The company even ran a small animal study to see how it was absorbed.
The company never announced the results though.
The Duke trial in glioblastoma used a direct injection of a dna modified Polio virus into the tumor.
The affects were in some patients great but looks like in attempting to hurry along the immune reaction by dose escalation too much (3X I believe) they may have caused such a severe immune response including inflammation in the brain that the patient died.
They then drastically reduced the dosage and appear in the patient they showed are getting a good, although slow results. It appears the immune system does not have to be overly stimulated to do its job and to push too hard is counter productive.
A huge difference with Advaxis' vaccine is their results are obtained with an out patient infusion, and not a direct intra tumoral infusion. In this case in a hospital. Much less application cost.
The biggest difference so far is the Advaxis vaccine has a global, whole body efficacy and there was no mention of the Duke Polio vaccine having any affect on metastasis, which for most cancers is the ultimate objective.
Most single tumors can be resected however brain tumors often cannot be successfully since they reside and spread within critical brain function areas. So this is what makes the Polio vaccine so valuable for brain
Sentiment: Strong Buy